NASDAQ: HSCSHeartsciences Inc Stock
$5.20+0.36 (+7.44%)
Updated Sep 18, 2026
HSCS Price
$5.20
Fair Value Price
N/A
Market Cap
$24.96M
52 Week Low
$1.63
52 Week High
$5.21
P/E
-1.62x
P/B
-12.28x
P/S
1,772.36x
PEG
N/A
Dividend Yield
N/A
Revenue
$4.52k
Earnings
-$10.26M
Gross Margin
60.9%
Operating Margin
-209,219.1%
Profit Margin
-227,024.2%
Debt to Equity
-2.84
Operating Cash Flow
-$7M
Beta
0.31
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
HSCS Overview
HeartSciences Inc. is a medical technology company dedicated to augmenting the clinical utility of electrocardiograms (ECGs) by integrating artificial intelligence (AI). The firm develops AI-enhanced ECG (AI-ECG) solutions, including an algorithm specifically designed to detect impaired cardiac relaxation or other forms of cardiac dysfunction, whether caused by heart disease or the natural aging process. Among its offerings is the MyoVista wavECG device, a 12-lead resting ECG that provides comprehensive diagnostic information concerning cardiac function alongside conventional ECG data in a single examination. Furthermore, the company offers MyoVista Insights, a cloud-based platform capable of hosting its AI-ECG algorithms across various ECG hardware systems. Established in 2007, HeartSciences Inc. operates from its headquarters in Southlake, Texas. The company was formerly named Heart Test Laboratories, Inc. until its rebranding to HeartSciences Inc. in October 2024.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine HSCS's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +5.11% per year. Learn More
Zen Rating Component Grades
F
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Be the first to know about important HSCS news, forecast changes, insider trades & much more!
HSCS News
Overview
Due Diligence Score
–
Industry Average (30)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how HSCS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
HSCS is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
HSCS is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
HSCS's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more HSCS due diligence checks available for Premium users.
Valuation
HSCS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.62x
Industry
22.31x
Market
44.48x
HSCS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-12.28x
Industry
3.07x
HSCS's financial health
Profit margin
Revenue
$2.1k
Net Income
-$3.2M
Profit Margin
-151,064%
HSCS's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
HSCS's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$3.7M
Liabilities
$5.8M
Debt to equity
-2.84
HSCS's short-term liabilities ($5.63M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
HSCS's short-term assets ($811.77k) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
HSCS's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
HSCS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.3M
Investing
-$280.1k
Financing
-$27.9k
HSCS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
HSCS vs Medical Device Stocks
Heartsciences Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.